Eli Lilly’s stock has risen more than 300% in five years and recently traded above $1,200, putting the drugmaker among the companies investors commonly discuss as potential stock-split candidates. The shares were above $1,160 in the latest context reviewed, after gaining about 25% over six months.
It would not change the value of an investor’s position or alter Lilly’s business fundamentals, but a lower per-share price could make the stock easier to buy for investors without access to fractional shares.
Lilly’s recent growth has been driven heavily by Mounjaro and Zepbound, its medicines in the GLP-1 market. The company competes with Novo Nordisk, whose portfolio includes Ozempic and Wegovy, while the supplied reporting places Lilly at about 60% of the U.S. Market and estimates that the broader GLP-1 market could approach $100 billion by the end of the decade.
The company’s latest expansion of that franchise came on April 1, 2026, when U.S. Regulators approved orforglipron, branded as Foundayo, for adults with obesity or certain weight-related conditions. Lilly began making the once-daily pill available in the United States on April 9 through LillyDirect, telehealth providers and retail pharmacies.
Foundayo is an oral, small-molecule GLP-1 drug that can be taken without food or water restrictions.
Lilly also broke ground in September on a planned $6. 5 billion manufacturing facility in northeast Houston.
Lilly has carried out stock splits before, but its official historical records show the most recent split occurred in 1997, nearly three decades ago. The company’s current investor materials list 2026 dividend activity but do not announce a new split, leaving the possibility speculative rather than a confirmed corporate decision.
Analysis: Lilly’s high share price, renewed stock momentum and expanding oral GLP-1 business provide reasons investors may keep watching for a split. A split itself, however, would change the share count and trading price without changing the company’s earnings, products or underlying valuation.